Unibest

Pharmaceutical intermediates

Eltrombopag Intermediates

6 pharmaceutical intermediates for Eltrombopag. Indication: Aplastic Anemia; Idiopathic Thrombocytopenic Purpura (ITP); Hepatitis C; Chronic Hepatitis C.

提交项目All intermediates

About Eltrombopag

Originator
Glaxosmithkline (Gsk)
Indication
Aplastic Anemia; Idiopathic Thrombocytopenic Purpura (ITP); Hepatitis C; Chronic Hepatitis C
Approved Date
11/29/2023
DS/DP
11/05/2038

Available intermediates

6 intermediates currently listed for Eltrombopag. Request specifications, documentation or a quotation for any item below.

Eltrombopag intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3'-aMino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid hydrochloride376591-97-8//
1-(3,4-DIMETHYLPHENYL)-3-METHYL-3-PYRAZOLIN-5-ONE18048-64-1//
2-HYDROXY-3''-NITRO-BIPHENYL-3-CARBOXYLIC ACID376591-95-6//
3-bromo-2-methoxyaniline116557-46-1//
3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID376592-93-7//
2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one277299-70-4//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopag OlamineEluxadoline

Building toward Eltrombopag?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →